BeiGene Ltd. (BGNE)
| Bid | 180.03 |
| Market Cap | 20.21B |
| Revenue (ttm) | 386.98M |
| Net Income (ttm) | -367.5M |
| EPS (ttm) | -8.19 |
| PE Ratio (ttm) | -22.55 |
| Forward PE | -150.11 |
| Analyst | n/a |
| Ask | 189.93 |
| Volume | 329,397 |
| Avg. Volume (20D) | 369,150 |
| Open | 184.00 |
| Previous Close | 183.81 |
| Day's Range | 183.91 - 187.42 |
| 52-Week Range | 126.97 - 248.16 |
| Beta | 0.63 |
About BGNE
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tu...
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
BeiGene Announces Global Licensing Agreement for MAT2A InhibitorSAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today ...
3 months ago · seekingalpha.com
BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And USBeiGene's TEVIMBRA was just approved by the European Commission. The drug is poised to enter the EU and just reached the US market in October. BeiGene's revenue per share has grown significantly, with...
3 months ago · businesswire.com
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSASAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company which intends to change its name to BeOne Medicines Ltd., today...